Proven Efficacy &
Safety Profile
AXERT tablets are indicated for the acute treatment of migraine with or without aura in adults. For the patient who often delays taking her migraine medication due to concerns of side effects, especially during the day. The proven efficacy and tolerability profile of AXERT could help you offer her an effective option.
Minimal side effects may give AXERT patients the confidence to treat earlier, which
could result in improved outcomes.
100 mg Sumatriptan Comparison
AXERT® shows comparable efficacy to sumatriptan5
Fewer adverse events with AXERT® 5
Back to the Top
50 mg Sumatriptan Comparison
In a randomized, double-blind, parallel-group, optimum-dose comparison of almotriptan 12.5 mg and sumatriptan 50 mg3 published in the Archives of Neurology, almotriptan demonstrated comparable relief with a lower incidence of side effects vs. sumatriptan 50 mg.
Patients experiencing headache relief4
Better tolerated than sumatriptan 50mg4
Incidence of treatment-related adverse events and chest pain4
Adapted From: Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine. Arch Neurol.2001;58:944-950.
Back to the TopAEGIS Study: Pain Relief Profile
A multicenter, randomized, double-blind, placebo controlled, parallel-group trial of 317 migraine patients was conducted to evaluate the efficacy and safety of AXERT in early migraine treatment. When patients took AXERT within one hour of headache onset, a greater number experienced pain relief (secondary endpoint) as early (primary endpoint) as 1 hour compared with placebo. More patients who took AXERT reported being pain free at 2 and 24 hours after 1 treatment. AXERT also demonstrated a side effect profile similar to placebo.
What if she treated earlier?
Early treatment with AXERT, within the first hour of a migraine attack,
provided significant pain relief.
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial of 317 migraine patients.
Adapted From: Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
AEGIS Study: Side Effect Profile
AXERT demonstrated a side effect profile similar to placebo3
Multicenter, randomized, double-blind, placebo controlled, parallel group trial of 317 migraine patients.
Adverse Events With an Incidence = 1% in Either Treatment Group
Adapted From: Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
Back to the TopDosing
In controlled clinical trials, single doses of 6.25 mg and 12.5 mg of AXERT tablets were effective for the acute treatment of migraines in adults, with the 12.5 mg dose tending to be a more effective dose. Individuals may vary in response to doses of AXERT. The choice of dose should therefore be made on an individual basis. If the headache returns, the dose may be repeated after 2 hours, but no more than two doses should be given within a 24-hour period.
Click here for Full Prescribing Information- Mathew NT, Finlayson G, Smith TR, et al, on behalf of the AEGIS Investigator Study Group. Early Intervention with Almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007;47:189-198.
- Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine. Arch Neurol. 2001;58:944-950.
- Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptain is an effective and generally well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002;22:453-461.
Indication
AXERT® tablets are indicated for the acute treatment of migraine with
or without aura in adults. AXERT® tablets are indicated for the acute
treatment of migraine headache pain in adolescents age 12 to 17 years
with a history of migraine attacks with or without aura usually
lasting 4 hours or more (when untreated). In adolescents age 12-17
years, efficacy of AXERT® on migraine associated symptoms (nausea,
photophobia and phonophobia) was not established.
AXERT® is not intended for the prophylactic therapy of migraine or for
use in the management of hemiplegic or basilar migraine. Safety and
effectiveness of AXERT® have not been established for cluster headache
which is present in an older, predominantly male population.
IMPORTANT SAFETY INFORMATION
AXERT® tablets should be used only when a clear diagnosis of
migraine has been established. If a patient has no response for the
first migraine attack treated with AXERT®, the diagnosis of
migraine should be reconsidered before AXERT® is administered to
treat any subsequent attacks. AXERT®, like other triptans, has
been associated with coronary vasospasm and therefore should not be
given to patients with ischemic heart disease or to patients who have
symptoms or findings consistent with ischemic heart disease, coronary
artery vasospasm (including Prinzmetal's variant angina), or other
significant underlying cardiovascular disease. AXERT®, like other
triptans in this class, should not be given to patients in whom
unrecognized coronary artery disease (CAD) is predicted by risk
factors (family history, high cholesterol, high blood pressure,
diabetes, or obesity). Do not use AXERT® in patients with
cerebrovascular syndromes including (but not limited to) stroke of any
type as well as transient ischemic attacks. Certain cerebrovascular
events and serious cardiac events have been reported in patients
treated with triptans, and some events have resulted in fatalities. Do
not use AXERT® in patients with peripheral vascular disease
including (but not limited to) ischemic bowel disease. Because
AXERT® may increase blood pressure, it should not be given to
patients with uncontrolled hypertension.
In very rare cases, serious cardiovascular events have been reported in association with AXERT® use in the absence of known cardiovascular disease. If treatment is considered, patients should first have a cardiovascular evaluation and the first dose should take place in a physician's office setting. Sensations of pain, tightness, pressure and heaviness in the chest, throat, neck, and jaw have been reported with AXERT® and other triptans. This is generally not associated with myocardial ischemia, but patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD. Patients who experience symptoms or signs suggestive of decreased arterial flow following the use of any triptan, such as ischemic bowel syndrome or Raynaud's syndrome, are candidates for further evaluation.
The development of a potentially life-threatening serotonin syndrome may occur with triptans, including AXERT® treatment, particularly when combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If combined treatment with AXERT® and an antidepressant is clinically warranted, patients should be closely observed for signs and symptoms of the serotonin syndrome such as mental status changes, hyperthermia, diaphoresis, labile blood pressure, tachycardia, hyperreflexia, incoordination and/or gastrointestinal symptoms, especially during treatment initiation and dosage escalation. Patients with the serotonin syndrome require immediate medical attention.
Do not use AXERT® within 24 hours of ergotamine-containing or ergot-type medications, or another 5-HT1 agonist (e.g. triptan). Patients taking ketoconazole need a lower dose of AXERT®. Do not use if known hypersensitivity exists to AXERT®. Use with caution in patients with known hypersensitivity to sulfonamides.
The most common side effects in adults are nausea, somnolence, paresthesia, headache and dry mouth.
The most common side effects in adolescents are dizziness, somnolence, headache, paresthesia, nausea and vomiting.
For more detailed information, please see full Prescribing Information.
©Janssen Pharmaceuticals, Inc. 2003-2011 . All rights reserved. Licensed from Almirall, S.A.. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.
Janssen Pharmaceuticals, Inc. publishes this site and is solely responsible for its contents. The TOPAMAX360.com, RAZADYNEER360.com, TOPAMAXEPILEPSY360.com, and AXERT360.com sites are directly affiliated with OMN360.com and the same terms of use apply across all sites.
Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc.
This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.
This page was last updated on Aug 16 2011 at 07:15:27 EDT.